Physician profile
Sameer Malhotra
NPI 1982656526
$7,967.95
in general payments reported to CMS, 2019-2025
38 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $270 · 2021: $812 · 2022: $935 · 2023: $1,162 · 2024: $2,249 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539 · Travel and Lodging: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.88 |
| Travel and Lodging | $392.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,164.59 | 2019-2024 | Xtandi, Myrbetriq |
| Teleflex LLC | $1,115.34 | 2021-2025 | Urolift, Barrigel, Solesta |
| Pfizer INC. | $874.74 | 2019-2025 | |
| Janssen Biotech, INC. | $797.24 | 2019-2025 | Erleada |
| Abbvie INC. | $597.92 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $548.21 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $251.84 | 2022-2025 | |
| Boston Scientific Corporation | $235.34 | 2019-2025 | Advantage System |
| Progenics Pharmaceuticals, INC. | $215.35 | 2023-2025 | Pylarify |
| Novartis Pharmaceuticals Corporation | $204.80 | 2019-2025 | |
| Coloplast Corp | $176.57 | 2019-2023 | Isiris Astent Removal Device |
| Merck Sharp & Dohme LLC | $165.91 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Calyxo, INC. | $146.06 | 2025 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $139.25 | 2024 | Aquabeam System |
| Axonics, INC. | $134.63 | 2022-2024 | Axonics, Bulkamid |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $133.25 | 2019-2025 | Provenge |
| Immunitybio, INC. | $130.19 | 2025 | |
| Urogen Pharma, INC. | $117.98 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $109.08 | 2021-2025 | Prolaris |
| Urovant Sciences INC | $89.40 | 2022 | |
| Blue Earth Diagnostics | $73.70 | 2023-2025 | Posluma |
| Endo USA, INC. | $63.64 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $60.10 | 2020-2023 | Xiaflex |
| Myovant Sciences INC. | $49.01 | 2021-2022 | |
| Allergan, INC. | $41.38 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $38.95 | 2021 | |
| Tolmar, INC. | $29.87 | 2025 | Eligard |
| Telix Pharmaceuticals | $29.85 | 2024 | Illuccix |
| Metuchen Pharmaceuticals | $29.34 | 2019 | |
| Amgen INC. | $26.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.37 | 2019 | |
| Hollister Incorporated | $23.94 | 2023 | Vapro, Vapro Pocket |
| Halozyme INC | $23.72 | 2023 | |
| Convatec INC. | $23.43 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.60 | 2024 | Adstiladrin |
| Rochester Medical Corporation | $20.77 | 2022 | |
| Angiodynamics, INC. | $20.37 | 2025 | Nanoknife |
| Smith+Nephew, INC. | $19.17 | 2023 | Stravix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.